Targeted glycemic control in type 2 diabetes.
Skyler
J S
JS
University of Miami, USA.
D000368:Aged; D000465:Algorithms; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D002839:Chromans / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D000078790:Insulin Secretion; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors; D009765:Obesity / Q000188:drug therapy; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D000077288:Troglitazone
D019440:Anti-Obesity Agents; D001645:Biguanides; D001786:Blood Glucose; D002839:Chromans; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D009687:Nuclear Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone